Five years after its debut, the world’s most-common malaria vaccine is on the market.
Now, a new trial will compare it to the best available vaccine in Africa.
The first phase of the trial is a three-year study that is expected to conclude by the end of 2018.
The goal is to compare the effectiveness of the three-dose regimen to a vaccine given to people in West Africa, where the disease is endemic and deadly.
The new vaccine is being developed by the Centers for Disease Control and Prevention’s National Institute of Allergy and Infectious Diseases, and is the first in a series of vaccines for malaria that will be administered in the U.S. and around the world starting in 2019.
In the current phase, the researchers will be testing a combination of three vaccines administered in sub-Saharan Africa.
The vaccines will be given to 4,500 adults, with the first being given to the largest sub-population, which is the most likely to receive the vaccine in the current study.
The researchers are also testing a second vaccine that will also be given in sub Africa and will target a different sub-populations, with a slightly smaller population.
This vaccine will be used in the next three years in West African countries where malaria is still endemic, including Kenya, Tanzania, Uganda and Rwanda.
It is the largest phase of a three year trial that will take place in West and Central Africa.
In total, the vaccine will target 2.7 million adults and their children.
This vaccine has a better safety record than the current vaccine.
As with the current dose, the study will compare the efficacy of the vaccine with the best vaccine available.
This is because the current and the new vaccines are identical in the way they work.
In other words, the new vaccine can be given safely to people with the disease and still protect them from the pandemic.
Currently, the pandemics vaccine can’t be administered to children under the age of 5.
To date, more than 50 countries in West, Central and Eastern Africa have administered the pandemeric vaccine.
However, the current batch of vaccines has been only available in two countries, and both countries are under severe strain from the epidemic.
The first phase was a five-year trial, which was interrupted due to the pandemia, and the second phase was four-year, with another four-day interruption due to pandemic, so the vaccines have yet to be deployed.
For the trial to be effective, the vaccination will have to work on the most important populations in the first place.
That means, for example, the elderly and people with chronic illnesses.
The vaccine also has to work to protect against those at higher risk of infection, such as people with pre-existing infections and people who have been exposed to the virus during the pandep.
Researchers hope to be able to compare outcomes between the current doses and the vaccine as it is being delivered in sub African countries.
That said, they don’t have any specific targets for the second dose.
The current phase of testing is aimed at children in sub Saharan Africa, so it’s possible the results could be skewed.
The two main goals of the study are to compare vaccine efficacy and safety, and to determine whether the vaccine is also more effective when given to adults, which will help determine whether it is more effective at preventing the pandewes pandemic or the spread of the disease.
Dr. Steven C. Goodman, who leads the NIH-sponsored research, said the results should help drive the next phase of vaccine development.
“We hope to get the vaccine out to the people that are most at risk for transmission, and this will give us some answers as to whether that vaccine is more likely to be safe and effective,” he said.
There are currently about 8.4 million people in sub Sahara, where malaria still occurs.
One of the most severe challenges to the vaccine, Goodman said, is that it is administered by an army of doctors in a country with limited medical resources.
That is why, in some countries, doctors are not able to get in to the field.
If that is the case, the CDC is looking to expand its testing to people living in the areas where malaria has been endemic, such the north and northeast, and that is where most of the new trials will be taking place.
More than 30,000 people died of malaria in sub countries during the recent pandemic and the pandemaker vaccine is one of the few vaccines currently available to those who are at high risk of transmission.